TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11571882
Drug: High-tech surgical
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-tech surgical treatment modalities
Study: 31597014
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg monophasic controlled-release oxycodone tablets
Study: 31597014
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral solution oxycodone
Study: 31597014
Drug: Controlled-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulations (both 20 mg tablets)
Study: 29945259
Drug: Herbal formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal formulations (shampoo and solution)
Study: 29945259
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of shampoo and solution
Study: 26228675
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (0.5 g/d for 3 wk, then 1 g/d)
Study: 21802126
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 2 months
Study: 21802126
Drug: 300 IR
Normalized name: ORALAIR 300 IR TAB,SL PKT 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 4 months
Study: 17138173
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of 4% articaine/HCl with 1:100,000 epinephrine injected into the buccal vestibule of the tooth
Study: 14650862
Drug: Fondaparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux (2.5 mg once daily for 21 +/- 2 days)
Study: 15508780
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (n = 32)
Study: 6666224
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (80 mg once daily)
Study: 6666224
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (80 mg twice daily)
Study: 20077492
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (5-ALA) at a dosage of 5 mg/kg body weight administered prior to surgery
Study: 17050563
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 25 mg alpha(1)-antitrypsin (AAT) daily for 4 weeks
Study: 16262741
Drug: Artesunate (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (4 mg/kg daily for 3 days) plus Amodiaquine (30 mg/kg over 3 days)
Study: 16262741
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg over 3 days) plus Pyrimethamine-Sulfadoxine (25 mg/kg of sulfadoxine at presentation)
Study: 9802119
Drug: Combined cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive-behavioral and pharmacological therapy (fluoxetine for AN-R and AN-BP, amineptine for AN-BP and BN, fluvoxamine for BN)
Study: 2506671
Drug: Heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin treatment (subcutaneously administered clinical grade heparin)
Study: 2506671
Drug: Nitrates and
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates and calcium-channel blockers without heparin
Study: 742831
Drug: Combined analgesic-relaxant
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined analgesic-relaxant anaesthesia
Study: 30203748
Drug: Glucosamine hydrochloride
Normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine hydrochloride tablets
Study: 30203748
Drug: Cervical vertebra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical vertebra exercises and cervical occipital belt traction therapy (reference group)
Study: 26461996
Drug: Early physical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early physical therapy (4 sessions)
Study: 24107292
Drug: Pitolisant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant (10 mg, 20 mg, or 40 mg a day)
Study: 24107292
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg, 200 mg, or 400 mg a day)
Study: 21396086
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tablet containing 1 mg vitamin B12
Study: 21396086
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: 11758131
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose nebulized albuterol (0.15 mg/kg)
Study: 11758131
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose nebulized albuterol (0.075 mg/kg) plus ipratropium-bromide (250 micrograms/dose)
Study: 9390958
Drug: CHO (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (0.75 g/kg) + Pro (0.1 g/kg) + Fat (0.02 g/kg)
Study: 8426322
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of gentamicin and dexamethasone
Study: 8426322
Drug: Collagen shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen shield without drug
Study: 3624680
Drug: mPEG-modified honeybee
Normalized name: MPEG 6000 acetyl lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mPEG-modified honeybee venom (200 micrograms maintenance dose)
Study: 3624680
Drug: unmodified honeybee
Approvals — FDA: no, EMA: no, PMDA: no
Description: unmodified honeybee venom (100 micrograms maintenance dose)
Study: 4573205
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment in epileptic patients
Study: 4573205
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in epileptic patients
Study: 4573205
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment in normal subjects
Study: 4573205
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in normal subjects
Study: 22835079
Drug: Parecoxib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (80 mg)
Study: 21076089
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PEM and MR imaging
Study: 12500005
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy in combination with Oral Rehydration Solution (ORS)
Study: 12500005
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with Oral Rehydration Solution (ORS)
Study: 8557897
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 24 hours
Study: 8557897
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 72 hours
Study: 8557897
Drug: Nitroglycerin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion (0.5 micrograms/kg body weight per min) for 0 hours (control group)
Study: 1988573
Drug: Standard two‐cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard two‐cycle therapy
Study: 1988573
Drug: Best induction/continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best induction/continuation therapy combination
Study: 1988573
Drug: Four‐cycle continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four‐cycle continuation therapy
Study: 6409493
Drug: Kinetically based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinetically based chemotherapy regimen before and after radiotherapy
Study: 22476168
Drug: Beta-alanine (BA)
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (BA) supplementation 4 g·d(‐1) for 1 week, then 6 g·d(‐1) for 4 weeks
Study: 22104710
Drug: Intranasal citrate
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal citrate (0.3 M solution)
Study: 22104710
Drug: Intranasal citrate
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal citrate with 2% lidocaine pretreatment
Study: 22104710
Drug: Intranasal citrate
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal citrate mixed with 2% lidocaine
Study: 10877199
Drug: Oral 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17beta-estradiol 2 mg daily with sequential oral norethindrone acetate (NETA) 1 mg daily from days 12 to 22
Study: 10877199
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol 0.05 mg daily with sequential oral NETA 1 mg daily from days 17 to 28
Study: 30901496
Drug: Diploid genotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diploid genotypes under low-water availability treatment
Study: 30901496
Drug: Hexaploid genotypes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexaploid genotypes under low-water availability treatment
Study: 30901496
Drug: Both diploid
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both diploid and hexaploid genotypes under temperature and watering treatments
Study: 30901496
Drug: Water availability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water availability treatment
Study: 30901496
Drug: Temperature treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature treatment
Study: 25255696
Drug: Immediate home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate home modifications (treatment group)
Study: 23178035
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amyloid PET and MTA data
Study: 21951559
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neuromuscular training program for 8 weeks and sports brace worn during all sports activities for 1 year
Study: 16527696
Drug: BIRB 796
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIRB 796 (10, 20, 30, or 60 mg twice daily for 8 weeks)
Study: 2871782
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day bevantolol
Study: 2871782
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day bevantolol
Study: 23732754
Drug: Interferon beta‐1b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1b, 250 μg, for at least 2 years
Study: 21097433
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib sodium (40 mg) at anesthesia induction (group A)
Study: 21097433
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib sodium (40 mg) 30 min before the completion of surgery (group B)
Study: 17399824
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and aldosterone antagonists
Study: 11028492
Drug: Systemic thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic thrombolytic therapy
Study: 11028492
Drug: High-dose thrombolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose thrombolysis
Study: 11028492
Drug: Conventional heparin/anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin/anticoagulation therapy
Study: 324863
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide gel (AG) 15 ml
Study: 324863
Drug: Dummy gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy gel (DG)
Study: 324863
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide gel (AG)
Study: 31841818
Drug: Zinc augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc augmentation
Study: 31488115
Drug: 16-week supervised
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 16-week supervised concurrent (aerobic and strength) exercise intervention program (3 sessions/week, 60 min/session)
Study: 16425130
Drug: O157-rEPA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: O157-rEPA vaccine (1 or 2 doses)
Study: 14635316
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction treatment
Study: 9129465
Drug: Fat-free soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free soup with olestra (33.3 g)
Study: 9129465
Drug: High-fat soup
Normalized name: MALT SOUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat soup (33.3 g fat)
Study: 27676671
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL contrast dye
Study: 27676671
Drug: 5.0 mL
Normalized name: ALCOHOL 65.0 mL in 100 mL TOPICAL LIQUID [FRESH DECOR COCONUT CREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mL contrast dye
Study: 23111427
Drug: 1-g vection
Normalized name: BENZOCAINE 5 g in 100 mL TOPICAL CREAM [Instant Erection]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g vection responses
Study: 20193857
Drug: Wrist arthroscopy
Normalized name: histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wrist arthroscopy for treatment and evaluation of scaphoid fracture and associated carpal injuries
Study: 11807347
Drug: Nerve and
Normalized name: Nerve and muscle antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve and tendon gliding exercises with splint treatment
Study: 11807347
Drug: Splint treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splint treatment only
Study: 1656818
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1 g in 500 ml of 5% glucose (Group B)
Study: 1656818
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 5% glucose (Group A)
Study: 29702118
Drug: Minimal therapist
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal therapist contact Cognitive Behavior Therapy (MC-CBT)
Study: 29702118
Drug: Standard Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Cognitive Behavior Therapy (S-CBT)
Study: 26692119
Drug: Tolvaptan (TLV)
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan (TLV) plus conventional treatment, n=26
Study: 26692119
Drug: Furosemide (FRM)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (FRM) increased dosage, n=26
Study: 26692119
Drug: Furosemide (FRM)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (FRM) increased dosage
Study: 25430726
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with praziquantel
Study: 12023696
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (diuretic/beta-blocker)
Study: 10366118
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/day for 2 years followed by 10 mg/day for 12-30 months
Study: 1784888
Drug: S-ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ibuprofen (400 mg T.I.D.)
Study: 1784888
Drug: Racemic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Racemic ibuprofen (600 mg T.I.D.)
Study: 7008642
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol powder (0.2 mg/dosis)
Study: 7008642
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol spray (0.1 mg/dosis)
Study: 27979034
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral anticoagulants (NOAC)
Study: 25458910
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment for 14 days
Study: 23203904
Drug: Nintendo-Wii Bowling,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintendo-Wii Bowling, 60 min/twice a week for 6 weeks
Study: 22741442
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg bid + VitE 100 mg tid
Study: 22741442
Drug: Levocarnitine oral
Normalized name: levocarnitine Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine oral solution 1 bottle bid + VitE 100 mg tid
Study: 22741442
Drug: Levocarnitine oral
Normalized name: levocarnitine Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocarnitine oral solution 1 bottle bid
Study: 19931288
Drug: Caffeine 250
Normalized name: caffeine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 250 mg (paired group)
Study: 19931288
Drug: Caffeine 250
Normalized name: caffeine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 250 mg (Experiment 2)
Study: 12536346
Drug: Maternal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vitamin K2 supplementation (15 mg/d Menatetrenone since the 14th day after parturition)
Study: 9824933
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 cc (100 mcg) three times daily subcutaneously for the first seven days post-operatively
Study: 7988247
Drug: Postoperative combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative combined chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP)
Study: 3185461
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg per os)
Study: 29400626
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (5 mg daily for 4 weeks, n=6)
Study: 26276750
Drug: Soy supplementation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplementation (50 mg isoflavones per day; n = 46)
Study: 23751235
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray with suggestion to increase BP
Study: 23751235
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray with suggestion to decrease BP
Study: 23751235
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray with no suggestion (controls)
Study: 15932725
Drug: Azathioprine (AzA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AzA) treatment after conversion from mycophenolate mofetil (MMF), n = 42
Study: 15932725
Drug: Continued mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued mycophenolate mofetil (MMF) treatment, n = 45
Study: 12667396
Drug: Peripancreatic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripancreatic arterial ligation and arterial infusion regional chemotherapy (Group B)
Study: 12667396
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy after surgery (Group A)
Study: 1839435
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg/day, adjustable to 10 mg/day after 4 weeks)
Study: 6133287
Drug: Clopenthixol decanoate
Normalized name: zuclopenthixol decanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopenthixol decanoate (100 mg 4-weekly to 400 mg 2-weekly)
Study: 6133287
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate (12.5 mg 4-weekly to 37.5 mg 3-weekly)
Study: 20117262
Drug: Vaxfectin-adjuvanted monovalent
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxfectin-adjuvanted monovalent plasmid DNA vaccine
Study: 20117262
Drug: Vaxfectin-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxfectin-adjuvanted trivalent plasmid DNA vaccine
Study: 17585668
Drug: Needling method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling method for harmonizing spleen-stomach, treated twice each day for 10 days
Study: 17585668
Drug: Motilium 10
Normalized name: Motilium 10 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motilium 10 mg, oral administration 3 times each day, 30 min before meals
Study: 7808491
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole or sulfin-pyrazone
Study: 30518685
Drug: Low-dose inhaled
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose inhaled carbon monoxide (iCO) at 100 ppm (cohort 1) or 200 ppm (cohort 2) for 90 minutes for up to 5 consecutive days
Study: 26701762
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (SSNB) with physical therapy